Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report

Zurich, 5th of May 2025: Xlife Sciences AG («Xlife Sciences»; SIX: XLS) today published its 2024 Valuation Report, evaluating the company’s project portfolio as of December 31, 2024.

The independent consulting firm CYLAD Consulting conducted the assessment, which covers 16 project companies within Xlife Sciences’ total portfolio¹. CYLAD Consulting based its assessment on financial forecasts and strategic plans, supplemented by site visits and discussions with the management of the respective project company. The evaluation was performed using the risk-adjusted net present value (rNPV) method, widely applied in the life sciences industry. Key parameters for the valuation included cost of capital and development risks specific to the project companies.

• The 2024 Valuation Report values Xlife Sciences' project portfolio within a range of CHF 617.4 million to CHF 754.7 million, compared to CHF 611.7 million to CHF 747.8 million in the previous year.


• The five largest project companies - alytas therapeutics GmbH, VERAXA Biotech AG, inflamed pharma GmbH, Inventum Genetics GmbH, and FUSE-AI GmbH - account for 88 percent of the total portfolio value.


• The «Technology Platforms» segment represents the largest share of the portfolio at 50 percent, followed by «Biotechnology/Therapies» with 38 percent.


• 76 percent of the portfolio value is attributed to projects in the «Proof of Concept» phase, while 12 percent of the portfolio value is already operational in the market.

Oliver R. Baumann, CEO of Xlife Sciences, commented: «The 2024 Valuation Report again confirms the strong potential of our portfolio. Our model of accelerating innovative projects from top academic institutions toward commercialization continues to create substantial value for our shareholders. We remain focused on strategic project development and selective international expansion, including the validation of our business model by transaction/partial exits as with the most recent VERAXA Biotech AG announcement.»

Following the intended capital market transaction of FUSE-AI GmbH and the associated offer from Pineapple Power Corporation PLC to acquire the company at an expected valuation of EUR 80-90 million and thus take it public (LSE, UK), additional incoming offers and opportunities were carefully reviewed. In close coordination with Xlife Sciences AG and other strategic partners, the company has decided to align a potential listing with the current valuation report (EUR 100-115 million) and, in consultation with strategic co-investors, to target the more attractive U.S. market. This approach aims to achieve broader market entry, faster scaling, and access to the necessary growth capital.

The full 2024 Valuation Report can be downloaded at: https://www.xlifesciences.ch/en/news-and-key-figures (Section «Financial Reports»)

¹ The eight project companies Firstgene Therapeutics GmbH, XRNA Biotech GmbH, xprot GmbH, novaxomx GmbH, Novum Technologie GmbH, Xsight Optics GmbH, QUADIRA BIOSCIENCES AG and 4D Lifetec AG were not evaluated.

Financial calendar

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange